Potential of adiponectin as a cardioprotective agent.

In this review, we focus on the role of adiponectin as a cardioprotective agent in several pathological heart conditions. Obesity is closely associated with Type 2 diabetes, hypertension and heart disease. Adiponectin is an adipose tissue-derived hormone whose concentration is downregulated in subjects with obesity-related diseases. Hypoadiponectinemia has been identified as an independent risk factor for Type 2 diabetes, coronary artery disease, acute coronary syndrome and hypertension. More recent experimental findings have shown that adiponectin directly affects signaling in cardiac myocytes and has beneficial effects on several pathological heart conditions, including cardiac hypertrophy and myocardial infarction. The favorable effects of adiponectin are associated with attenuated inflammatory response, decreased myocyte death, decreased hypertrophic response, maintained ischemia-induced angiogenesis and reduced interstitial fibrosis. Therefore, adiponectin could represent a molecular target for treating obesity-linked cardiac diseases.

[1]  D. Levy,et al.  Impact of Glucose Intolerance and Insulin Resistance on Cardiac Structure and Function: Sex-Related Differences in the Framingham Heart Study , 2003, Circulation.

[2]  Nimesh Mody,et al.  Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes , 2005, Nature.

[3]  K. Choi,et al.  Serum adiponectin concentrations predict the developments of type 2 diabetes and the metabolic syndrome in elderly Koreans , 2004, Clinical endocrinology.

[4]  S. Kihara,et al.  Selective Suppression of Endothelial Cell Apoptosis by the High Molecular Weight Form of Adiponectin , 2004, Circulation research.

[5]  H. Lodish,et al.  T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[6]  T. Funahashi,et al.  Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. , 2001, Diabetes.

[7]  Philippe Froguel,et al.  Cloning of adiponectin receptors that mediate antidiabetic metabolic effects , 2003, Nature.

[8]  T Nakamura,et al.  Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. , 1999, Circulation.

[9]  S. Kihara,et al.  Association of Hypoadiponectinemia With Coronary Artery Disease in Men , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[10]  S. Higano,et al.  Obesity is independently associated with coronary endothelial dysfunction in patients with normal or mildly diseased coronary arteries. , 2001, Journal of the American College of Cardiology.

[11]  J. Engel,et al.  Structure-Function Studies of the Adipocyte-secreted Hormone Acrp30/Adiponectin , 2003, The Journal of Biological Chemistry.

[12]  A Hofman,et al.  The prognosis of heart failure in the general population: The Rotterdam Study. , 2001, European heart journal.

[13]  Philippe Froguel,et al.  Disruption of Adiponectin Causes Insulin Resistance and Neointimal Formation* , 2002, The Journal of Biological Chemistry.

[14]  S. Kihara,et al.  Adiponectin Stimulates Angiogenesis in Response to Tissue Ischemia through Stimulation of AMP-activated Protein Kinase Signaling* , 2004, Journal of Biological Chemistry.

[15]  Y. Nakano,et al.  Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. , 1996, Journal of biochemistry.

[16]  Y. Sharabi,et al.  Circulating adiponectin concentrations in patients with congestive heart failure , 2006, Heart.

[17]  H. Lodish,et al.  Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[18]  M. Eguchi,et al.  Globular and full-length forms of adiponectin mediate specific changes in glucose and fatty acid uptake and metabolism in cardiomyocytes. , 2007, Cardiovascular research.

[19]  H. Fechner,et al.  Genomic expression profiling of human inflammatory cardiomyopathy (DCMi) suggests novel therapeutic targets , 2006, Journal of Molecular Medicine.

[20]  Jan Frystyk,et al.  Plasma Adiponectin, Body Mass Index, and Mortality in Patients With Chronic Heart Failure , 2005, Circulation.

[21]  Jonathan Krakoff,et al.  Adiponectin and development of type 2 diabetes in the Pima Indian population , 2002, The Lancet.

[22]  Y. Shimada,et al.  Implications of plasma concentrations of adiponectin in patients with coronary artery disease , 2004, Heart.

[23]  H. Boeing,et al.  Adiponectin and protection against type 2 diabetes mellitus , 2003, The Lancet.

[24]  S. Kihara,et al.  Adipocyte-Derived Plasma Protein, Adiponectin, Suppresses Lipid Accumulation and Class A Scavenger Receptor Expression in Human Monocyte-Derived Macrophages , 2001, Circulation.

[25]  T. Nojima,et al.  Adiponectin, T-cadherin and Tumour Necrosis Factor-α in Damaged Cardiomyocytes from Autopsy Specimens , 2005, The Journal of international medical research.

[26]  S. Kihara,et al.  Adiponectin Inhibits Endothelial Synthesis of Interleukin-8 , 2005, Circulation research.

[27]  P. Erne,et al.  Expression of adhesion molecule T-cadherin is increased during neointima formation in experimental restenosis , 2002, Histochemistry and Cell Biology.

[28]  Lei Guo,et al.  Calreticulin in the heart , 2004, Molecular and Cellular Biochemistry.

[29]  Kunihiro Suzuki,et al.  Stimulated HSP90 binding to eNOS and activation of the PI3-Akt pathway contribute to globular adiponectin-induced NO production: vasorelaxation in response to globular adiponectin. , 2005, Biochemical and biophysical research communications.

[30]  J. Friedman.  A War on Obesity, Not the Obese , 2003, Science.

[31]  Elizabeth Murphy,et al.  Cyclooxygenase-1 and -2 Knockout Mice Demonstrate Increased Cardiac Ischemia/Reperfusion Injury but Are Protected by Acute Preconditioning , 2001, Circulation.

[32]  S. Kihara,et al.  Adipocyte-Derived Plasma Protein Adiponectin Acts as a Platelet-Derived Growth Factor-BB–Binding Protein and Regulates Growth Factor–Induced Common Postreceptor Signal in Vascular Smooth Muscle Cell , 2002, Circulation.

[33]  S. Kihara,et al.  Adiponectin modulates inflammatory reactions via calreticulin receptor-dependent clearance of early apoptotic bodies. , 2007, The Journal of clinical investigation.

[34]  E. Rimm,et al.  Adiponectin and future coronary heart disease events among men with type 2 diabetes. , 2005, Diabetes.

[35]  J. Danesh,et al.  Adiponectin and Coronary Heart Disease: A Prospective Study and Meta-Analysis , 2006, Circulation.

[36]  Marc A Pfeffer,et al.  Cardiovascular Risk Associated With Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention , 2005, The New England journal of medicine.

[37]  B. Howard,et al.  Adiponectin and coronary heart disease: the Strong Heart Study. , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[38]  H. Nishimatsu,et al.  Statins Augment Collateral Growth in Response to Ischemia but They Do Not Promote Cancer and Atherosclerosis , 2004, Hypertension.

[39]  T Nakamura,et al.  Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[40]  S. Kihara,et al.  Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. , 2000, Blood.

[41]  Walter Koch,et al.  Adiponectin Cardioprotection After Myocardial Ischemia/Reperfusion Involves the Reduction of Oxidative/Nitrative Stress , 2007, Circulation.

[42]  M. Cnop,et al.  Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex , 2003, Diabetologia.

[43]  R. Kitazawa,et al.  MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. , 2006, The Journal of clinical investigation.

[44]  T. Funahashi,et al.  cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). , 1996, Biochemical and biophysical research communications.

[45]  S. Kihara,et al.  Adiponectin Specifically Increased Tissue Inhibitor of Metalloproteinase-1 Through Interleukin-10 Expression in Human Macrophages , 2004, Circulation.

[46]  R. Piñeiro,et al.  Adiponectin is synthesized and secreted by human and murine cardiomyocytes , 2005, FEBS letters.

[47]  H. Motoshima,et al.  Adiponectin suppresses proliferation and superoxide generation and enhances eNOS activity in endothelial cells treated with oxidized LDL. , 2004, Biochemical and biophysical research communications.

[48]  S. Kihara,et al.  Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. , 2002, Journal of the American Society of Nephrology : JASN.

[49]  J. Meyer-Kirchrath,et al.  Reduction of infarct size by selective stimulation of prostaglandin EP(3)receptors in the reperfused ischemic pig heart. , 2000, Journal of molecular and cellular cardiology.

[50]  K. Shimamoto,et al.  Possible impairment of transcardiac utilization of adiponectin in patients with type 2 diabetes. , 2004, Diabetes care.

[51]  S. Kihara,et al.  Adiponectin protects against the development of systolic dysfunction following myocardial infarction. , 2007, Journal of molecular and cellular cardiology.

[52]  S. Narumiya,et al.  Prostaglandin E2 Protects the Heart From Ischemia-Reperfusion Injury via Its Receptor Subtype EP4 , 2004, Circulation.

[53]  Robert Wolk,et al.  Body Mass Index: A Risk Factor for Unstable Angina and Myocardial Infarction in Patients With Angiographically Confirmed Coronary Artery Disease , 2003, Circulation.

[54]  S. Kihara,et al.  Adiponectin, an Adipocyte-Derived Plasma Protein, Inhibits Endothelial NF-&kgr;B Signaling Through a cAMP-Dependent Pathway , 2000, Circulation.

[55]  B. Murphy,et al.  Expression of adiponectin and its receptors in swine. , 2005, Journal of animal science.

[56]  M. Kurabayashi,et al.  Impaired expression of cardiac adiponectin in leptin-deficient mice with viral myocarditis. , 2006, International heart journal.

[57]  A. Xu,et al.  Adiponectin Inhibits Cell Proliferation by Interacting with Several Growth Factors in an Oligomerization-dependent Manner* , 2005, Journal of Biological Chemistry.

[58]  T Nakamura,et al.  Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. , 1999, Biochemical and biophysical research communications.

[59]  M. Hori,et al.  AMP-Activated Protein Kinase Protects Cardiomyocytes against Hypoxic Injury through Attenuation of Endoplasmic Reticulum Stress , 2005, Molecular and Cellular Biology.

[60]  S. Kihara,et al.  Adiponectin-mediated modulation of hypertrophic signals in the heart , 2004, Nature Medicine.

[61]  T. Funahashi,et al.  Exacerbation of heart failure in adiponectin-deficient mice due to impaired regulation of AMPK and glucose metabolism. , 2005, Cardiovascular research.

[62]  S. Kihara,et al.  Adiponectin as a biomarker of the metabolic syndrome. , 2004, Circulation journal : official journal of the Japanese Circulation Society.

[63]  H. Yatsuya,et al.  Adiponectin Level and Left Ventricular Hypertrophy in Japanese Men , 2007, Hypertension.

[64]  T. Kanda,et al.  Inhibition of cyclooxygenase-2 enhances myocardial damage in a mouse model of viral myocarditis. , 2005, Life sciences.

[65]  Philipp E. Scherer,et al.  A Novel Serum Protein Similar to C1q, Produced Exclusively in Adipocytes (*) , 1995, The Journal of Biological Chemistry.

[66]  H. Sumino,et al.  Adiponectin Replacement Therapy Attenuates Myocardial Damage in Leptin-deficient Mice with Viral Myocarditis , 2005, The Journal of international medical research.

[67]  M. Horie,et al.  Total and high molecular weight adiponectin, haemodynamics, and mortality in patients with chronic heart failure. , 2007, European heart journal.

[68]  M. Birnbaum,et al.  AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury. , 2004, The Journal of clinical investigation.

[69]  Kunihiro Suzuki,et al.  Globular Adiponectin Activates Nuclear Factor-κB and Activating Protein-1 and Enhances Angiotensin II–Induced Proliferation in Cardiac Fibroblasts , 2007, Diabetes.

[70]  S. Kihara,et al.  Erratum , 2003, Heart.

[71]  Y. Hattori,et al.  Globular adiponectin upregulates nitric oxide production in vascular endothelial cells , 2003, Diabetologia.

[72]  P. Scherer,et al.  Adipose tissue, inflammation, and cardiovascular disease. , 2005, Circulation research.

[73]  S. Brichard,et al.  Induction of adiponectin in skeletal muscle of type 2 diabetic mice: in vivo and in vitro studies , 2006, Diabetologia.

[74]  Hui Chen,et al.  Adiponectin Stimulates Production of Nitric Oxide in Vascular Endothelial Cells* , 2003, Journal of Biological Chemistry.

[75]  Cynthia J. Girman,et al.  Plasma adiponectin levels and risk of myocardial infarction in men. , 2004, JAMA.

[76]  Takamitsu Nakamura,et al.  Role of adiponectin receptors in endothelin-induced cellular hypertrophy in cultured cardiomyocytes and their expression in infarcted heart. , 2006, American journal of physiology. Heart and circulatory physiology.

[77]  D. Labarthe,et al.  The Relation of Diabetes to the Severity of Acute Myocardial Infarction and Post-Myocardial Infarction Survival in Mexican-Americans and Non-Hispanic Whites: The Corpus Christi Heart Project , 1994, Diabetes.

[78]  S. Kihara,et al.  Adiponectin Stimulates Angiogenesis by Promoting Cross-talk between AMP-activated Protein Kinase and Akt Signaling in Endothelial Cells* , 2004, Journal of Biological Chemistry.

[79]  S. Kihara,et al.  Adiponectin Reduces Atherosclerosis in Apolipoprotein E-Deficient Mice , 2002, Circulation.

[80]  M. Matsuda,et al.  Role of Adiponectin in Preventing Vascular Stenosis , 2002, The Journal of Biological Chemistry.

[81]  J. Ninomiya-Tsuji,et al.  AMP-Activated Protein Kinase Activates p38 Mitogen-Activated Protein Kinase by Increasing Recruitment of p38 MAPK to TAB1 in the Ischemic Heart , 2005, Circulation research.

[82]  S. Haffner,et al.  Plasma adiponectin is an independent predictor of type 2 diabetes in Asian indians. , 2003, Diabetes care.

[83]  H. Seo,et al.  Associations among plasma adiponectin, hypertension, left ventricular diastolic function and left ventricular mass index , 2004, Blood pressure.

[84]  C. Zoccali,et al.  Atherosclerotic renal artery stenosis: epidemiology, cardiovascular outcomes, and clinical prediction rules. , 2002, Journal of the American Society of Nephrology : JASN.

[85]  D. Lawlor,et al.  Plasma adiponectin levels are associated with insulin resistance, but do not predict future risk of coronary heart disease in women. , 2005, The Journal of clinical endocrinology and metabolism.

[86]  Gary Friedman,et al.  Magnetically driven plasmid DNA delivery with biodegradable polymeric nanoparticles , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[87]  E. Ingelsson,et al.  Adiponectin and risk of congestive heart failure. , 2006, Journal of the American Medical Association (JAMA).

[88]  Y. Saitoh,et al.  Transcardiac adiponectin gradient is independently related to endothelial vasomotor function in large and resistance coronary arteries in humans. , 2006, American journal of physiology. Heart and circulatory physiology.

[89]  T. Ogihara,et al.  Association of Hypoadiponectinemia With Impaired Vasoreactivity , 2003, Hypertension.

[90]  A. Baron,et al.  Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. , 1996, The Journal of clinical investigation.

[91]  T. Funahashi,et al.  Future adverse cardiac events can be predicted by persistently low plasma adiponectin concentrations in men and marked reductions of adiponectin in women after acute myocardial infarction. , 2007, Atherosclerosis.

[92]  S. Kihara,et al.  Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2–dependent mechanisms , 2005, Nature Medicine.

[93]  S. Kihara,et al.  Adiponectin accumulates in myocardial tissue that has been damaged by ischemia-reperfusion injury via leakage from the vascular compartment. , 2007, Cardiovascular research.

[94]  Qinglin Yang,et al.  Adiponectin and its receptors are expressed in adult ventricular cardiomyocytes and upregulated by activation of peroxisome proliferator-activated receptor gamma. , 2007, Journal of molecular and cellular cardiology.

[95]  T. Saruta,et al.  Adiponectin, an adipocyte-derived protein, predicts future insulin resistance: two-year follow-up study in Japanese population. , 2004, The Journal of clinical endocrinology and metabolism.

[96]  Robert Riddell,et al.  Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. , 2005, The New England journal of medicine.

[97]  Anita Y. M. Chan,et al.  Activation of AMP-activated Protein Kinase Inhibits Protein Synthesis Associated with Hypertrophy in the Cardiac Myocyte* , 2004, Journal of Biological Chemistry.

[98]  S. Kihara,et al.  Adiponectin Replenishment Ameliorates Obesity-Related Hypertension , 2006, Hypertension.

[99]  B. Howard,et al.  Relationship of impaired glucose tolerance to left ventricular structure and function: The Strong Heart Study. , 2001, American heart journal.

[100]  S. Kihara,et al.  Obesity, adiponectin and vascular inflammatory disease , 2003, Current opinion in lipidology.

[101]  S. Kihara,et al.  Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[102]  T. Ogihara,et al.  Hypoadiponectinemia Is an Independent Risk Factor for Hypertension , 2004, Hypertension.

[103]  B. Spiegelman,et al.  AdipoQ Is a Novel Adipose-specific Gene Dysregulated in Obesity (*) , 1996, The Journal of Biological Chemistry.

[104]  S. Anker,et al.  Insights into the pathogenesis of chronic heart failure: immune activation and cachexia. , 1999, Current opinion in cardiology.

[105]  M. Reilly,et al.  The Metabolic Syndrome: More Than the Sum of Its Parts? , 2003, Circulation.

[106]  K. Takahashi,et al.  Change in expression of GBP28/adiponectin in carbon tetrachloride-administrated mouse liver. , 2001, Biochemical and biophysical research communications.

[107]  R. Bolli,et al.  Discovery of a new function of cyclooxygenase (COX)-2: COX-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning. , 2002, Cardiovascular research.

[108]  S. Kihara,et al.  Disturbed secretion of mutant adiponectin associated with the metabolic syndrome. , 2003, Biochemical and biophysical research communications.